The authors wish to make the following corrections to this paper \[[@B1-jpm-08-00018]\], due to typographical errors:

On page 6, the sentence, "A time *t~ij~* (i.e., sum of accrual time and follow-up time) is generated for each patient, and if *t~ij~* is greater than the cutoff time then it is assumed that the patient encountered the event at *t~ij~*, otherwise the patient's event time is censored at *t~ij~*" should be "A time *t~ij~* (i.e., sum of accrual time and follow-up time) is generated for each patient, and if *t~ij~* is less than the cutoff time then it is assumed that the event was observed at *t~ij~*, otherwise the patient's event time is censored at *t~ij~*".

They would also like to remove the word *log rank* in page 11 in the four following cases:

"For the biomarker-negative subgroup of the two-stage adaptive design which tests the efficacy of the experimental treatment, the stopping rules are the following: Stage 1:Reject the null hypothesis (stop for efficacy) if *T'*~1−~ ≤ ε~1−~Do not reject the null hypothesis (stop for futility) if *T'*~1−~ \> *b*~1−~Continue to the second stage if ε~1−~ \< *T'*~1−~ ≤ *b*~1−~ where 0 \< ε~1−~ \< *b*~1−~ ≤ 1 and *T'*~1−~ refers to the [log-rank]{.ul} test statistic in the biomarker-negative subgroup at the first stage of the study, Stage 2:Reject the null hypothesis (stop for efficacy) if *T'*~2−~ ≤ ε~2−~Do not reject the null hypothesis (stop for futility) if *T'*~2−~ \> ε~2−~ where *T'*~2−~ refers to the [log-rank]{.ul} test statistic in the biomarker-negative subgroup at the second stage of the study.

For the biomarker-positive subgroup of the two-stage adaptive design which tests the efficacy of the experimental treatment, the stopping rules are the following, Stage 1:Reject the null hypothesis (stop for efficacy) if *T'*~1+~ ≤ ε~1+~Do not reject the null hypothesis (stop for futility) if *T'*~1+~ \> *b*~1+~Continue to the second stage if ε~1+~ \< *T'*~1+~ ≤ *b*~1+~ where 0 \< *a*~1+~ \< *b*~1+~ ≤ 1 and *T'*~1+~ refers to the [log-rank]{.ul} test statistic in the biomarker-positive subgroup at the first stage of the study, Stage 2:Reject the null hypothesis (stop for efficacy) if *T'*~2+~ ≤ ε~2+~Do not reject the null hypothesis (stop for futility) if *T'*~2+~ \> ε~2+~ where *T'*~2+~ refers to the [log-rank]{.ul} test statistic in the biomarker-positive subgroup at the second stage of the study."

These changes have no material impact on the conclusions of the paper. The authors would like to apologize for any inconvenience caused to the readers by these changes.
